Evidence map›Paper›PMID 37178669›Full record

GuidelineESMO open2023

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer.

S-A Im, A Gennari, Y H Park, J H Kim, Z-F Jiang, S Gupta, T H Fadjari, K Tamura, M Y Mastura, M L T Abesamis-Tiambeng and 21 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in ESMO open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Sacituzumab govitecan in HRNature medicine · 2024
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

S-A ImDepartment of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea. Electronic address: moisa@snu.ac.kr.
A GennariDepartment of Translational Medicine, University Piemonte Orientale, Novara, Italy.
Y H ParkDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
J H KimDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea.
Z-F JiangDepartment of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
S GuptaTata Memorial Centre and Homi Bhabha National Institute, Mumbai, India.
T H FadjariDepartment of Internal Medicine, Hasan Sadikin General Hospital, Bandung, Indonesia.
K TamuraDepartment of Medical Oncology, Shimane University Hospital, Shimane, Japan.
M Y MasturaCancer Centre, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.
M L T Abesamis-TiambengSection of Medical Oncology, Department of Internal Medicine, Cardinal Santos Cancer Center, San Juan, The Philippines.
E H LimDivision of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
C-H LinDepartment of Medical Oncology, National Taiwan University Hospital, Cancer Center Branch, Taipei, Taiwan.
A SookprasertDepartment of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
N ParinyanitikulMedical Oncology Unit, Department of Medicine, Faculty of Medicine, King Chulalongkorn Memorial Hospital and Chulalongkorn University, Bangkok, Thailand.
L-M TsengTaipei-Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
S-C LeeDepartment of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), Singapore, Singapore.
P CaguioaThe Cancer Institute of St Luke's Medical Center, National Capital Region, The Philippines; The Cancer Institute of the University of Santo Tomas Hospital, National Capital Region, The Philippines.
M SinghDepartment of Radiotherapy, Pantai Cancer Institute, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia; Department of Oncology, Pantai Cancer Institute, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.
Y NaitoDepartment of General Internal Medicine, National Cancer Center Hospital East, Kashiwa, Japan.
R A HukomDepartment of Hematology and Medical Oncology, Dharmais Hospital (National Cancer Center), Jakarta, Indonesia.
B K SmrutiMedical Oncology, Lilavati Hospital and Research Centre and Bombay Hospital Institute of Medical Sciences, Mumbai, India.
S-S WangCancer Center, Sun Yat-sen University, Guangzhou, China.
S B KimDepartment of Oncology, Asan Medical Centre, Seoul, Republic of Korea.
K-H LeeDepartment of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea.
H K AhnDivision of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea.
S PetersOncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
T W KimAsan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
T YoshinoDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
G PentheroudakisESMO, Lugano, Switzerland.
G CuriglianoIstituto Europeo di Oncologia, IRCCS, Milan, Italy; Department of Oncology and Haematology, University of Milano, Milan, Italy.
N HarbeckBreast Center, Department of Obstetrics and Gynaecology and Comprehensive Cancer Center Munich, LMU University Hospital, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer (MBC) was published in 2021. A special, hybrid guidelines meeting was convened by ESMO and the Korean Society of Medical Oncology (KSMO) in collaboration with nine other Asian national oncology societies in May 2022 in order to adapt the ESMO 2021 guidelines to take into account the differences associated with the treatment of MBC in Asia. These guidelines represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with MBC representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). The voting was based on the best available scientific evidence and was independent of drug access or practice restrictions in the different Asian countries. The latter were discussed when appropriate. The aim of these guidelines is to provide guidance for the harmonisation of the management of patients with MBC across the different regions of Asia, drawing from data provided by global and Asian trials whilst at the same time integrating the differences in genetics, demographics and scientific evidence, together with restricted access to certain therapeutic strategies.

Indexed as

Breast NeoplasmsAsiaFemaleHumansIndiaMedical OncologySocieties, MedicalESMOguidelinesmetastatic breast cancerPan-Asiantreatment

Identifiers

PMID37178669
PMCPMC10186487

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.